Usefulness of the (F/T)/PSA density ratio to detect prostate cancer

Urologia Internationalis

Volumn 74, Issue 1, 2005, Pages 13-18

  Veneziano, Salvatore ^a   Pavlica, Pietro ^a   Compagnone, Gaetano ^a   Martoran, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Free prostate specific antigen; Percent free prostate specific antigen; Prostate cancer; Prostate specific antigen; Prostate specific antigen density

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DENSITY; ECHOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; BLOOD; PROSTATE TUMOR;

AGED; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 18344384087     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082702     Document Type: Article

References (19)

1. Hudson ML, Bahson RR, Catalona WJ: Clinical use of prostatic specific antigen in patients with prostate cancer. J Urol 1989;142:101-107.
2. Veneziano S, Pavlica P, Querzè R, Nanni G, Lalanne MG, Vecchi F: Correlation between prostate specific antigen and prostate volume, evaluated by transrectal ultrasonography: Usefulness in diagnosis of prostate cancer. Eur Urol 1990;18:112-116.
3. Babaian RJ, Pritsche HA, Evans RB: Prostate-specific antigen and prostate gland volume correlation and clinical application. J Clin Lab Anal 1990;4:135-137.
4. Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: A decade of discovery - what we have learned and where we are going. J Urol 1999;162:293-306.
5. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T: Prostate specific antigen in serum occurs predominantly in complex with alpha-1-antichymotripsin. Clin Chem 1991;37:1618-1625.
6. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson KK, Pironen T, Abrahamsson PA, Stenman UHG, Dowell B, Lovgren T, Lilja H: Free, complexed and total serum prostate specific antigen. The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995;154:1090-1095.
7. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, Stamey TA: A comparison of the fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario. J Urol 1996;156:350-354.
8. Stenman UH, Leinonen J, Alfthan H, Rannikko S Tuhkanen K, Alfthan K: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
9. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M, Cockett ATK, Abrahamsson PA, Lilja H: Serum prostate specific antigen complexed to alpha1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.
10. Bjork T, Bjartell A, Abrahamsson PA, Hulkko S, di Sant'Agnese A, Lilja H: Alpha 1-antichymotrypsin production in PSA producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994;43:427-432.
11. Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, Munoz A, Id M'Hammed Y, de Torres IM: The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml. Eur Urol 2002;42:333-337.
12. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse H, Radiff TL Nadler RB: Evaluation of percentage of free serum prostate specific improve specificity of prostate cancer screening. JAMA 1995;274:1214-1219.
13. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology 1996; 48(6A suppl):55-61.
14. Stephan C, Lein M, Jung K, Schnorr D, Loening S: The influence of prostate volume on ratio of free to total prostate specific antigen serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79:104-109.
15. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, de-Kernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279:1542-1547.
16. Baltaci S, Aksoy H, Turkolmez, Elhan A. Ozden E, Gogus O: Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels. Urol Int 2003;70:36-41.
17. Metz C: Application of ROC analysis in diagnostic image evaluation; in Haus AG (ed): The Physics of Medical Imaging: Recording System Measurements and Techniques. New York, American Institute of Physics, 1979, pp 546-572.
18. Hanley JA, McNeil BJU: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
19. Cupp MR, Oesterling JE: Detecting early prostate cancer. AUA Update Ser 1993;12:33,258-263.